Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant gains in constituent stocks, indicating a positive trend in the healthcare sector [3]. Group 1: Market Performance - As of July 4, 2025, the HSHCI rose by 1.19%, with notable increases in stocks such as Huahao Zhongtian Pharmaceutical-B (02563) up 16.34% and Kangfang Biotech (09926) up 8.67% [3]. - The Hang Seng Healthcare ETF (513060) increased by 0.86%, with a latest price of 0.59 yuan, and has seen a cumulative increase of 3.57% over the past week [3]. - The ETF recorded a turnover rate of 18.66% during the trading session, with a transaction volume of 1.516 billion yuan, indicating active market participation [3]. Group 2: Investment Opportunities - Huatai Securities suggests that AI is expected to reshape drug development and healthcare service delivery, with increasing applications in the medical field, highlighting potential investment opportunities by 2025 [4]. - The Hang Seng Healthcare ETF has seen a significant growth in scale, with an increase of 191 million yuan over the past week, ranking in the top third among comparable funds [4]. - Leveraged funds are actively investing, with the latest financing buy-in amounting to 291 million yuan and a financing balance of 277 million yuan [4]. Group 3: Performance Metrics - The Hang Seng Healthcare ETF has achieved a net value increase of 18.78% over the past two years, with a maximum monthly return of 28.34% since inception [4]. - The ETF has outperformed its benchmark with an annualized excess return of 1.73% over the past year, and a Sharpe ratio of 1.85 as of June 27, 2025 [4]. - The ETF has the lowest drawdown among comparable funds, with a relative drawdown of 0.45% year-to-date [4]. Group 4: Fee Structure and Valuation - The management fee for the Hang Seng Healthcare ETF is 0.50%, and the custody fee is 0.15% [5]. - The ETF's tracking error over the past year is 0.069%, the highest tracking precision among comparable funds [5]. - The latest price-to-earnings ratio (PE-TTM) for the HSHCI is 27.68, indicating a valuation below 90.41% of the historical data over the past three years, suggesting it is at a historical low [5]. Group 5: Index Composition - The top ten weighted stocks in the HSHCI account for 58.46% of the index, including companies like Innovent Biologics (01801) and BeiGene (06160) [5].

港股午评：早盘港股主要股指下挫 创新药概念股持续上涨 金十数据7月4日讯，港股上午盘三大指数探底回升，临近早盘收盘跌幅收窄。截至午间收盘，恒生指数 跌0.62%，恒生科技指数跌0.47%。板块个股方面，港股中资券商股盘中再度活跃，国泰君安国际 (01788.HK)涨超20%，弘业期货(03678.HK)涨超7%。港股内银股走高，广州农商银行(01551.Hk)涨超 8%，民生银行(01988.HK)、贵州银行(06199.HK)涨超3%。创新药概念股持续上涨，康方生物 (09926.HK)涨超8%，药明合联(02268.HK)涨4.77%。 ...

Core Viewpoint - The pharmaceutical sector is experiencing significant movements, particularly with AstraZeneca exploring a potential $15 billion deal with SMMT, indicating strong interest in the PD(L)1*VEGF market, which is expected to grow substantially by 2030 [1][2]. Group 1: Market Performance - As of July 4, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) shows mixed performance among its constituent stocks, with Kangfang Biotech (09926) leading with a 3.86% increase [1]. - The Hong Kong Pharmaceutical ETF (159718) has seen a net value increase of 67.88% over the past year, currently priced at 0.86 yuan [1]. - The CSI Pharmaceutical and Medical Device Innovation Index (931484) has risen by 0.01%, with notable gains from stocks like Baillie Gifford (688506) and Kanghong Pharmaceutical (002773) [5][10]. Group 2: AstraZeneca's Strategic Moves - AstraZeneca is in discussions with SMMT regarding a potential $15 billion transaction, reflecting its strong positioning in the oncology sector and the need for a quality IO asset [1]. - The company is expected to generate 14 billion yuan in operating cash flow by 2025, with half available for business development and acquisitions, indicating a robust financial position to pursue significant transactions [1]. Group 3: PD(L)1*VEGF Market Insights - The PD(L)1*VEGF market is projected to reach $100 billion by 2030, with 42 approved indications, primarily in lung, stomach, kidney, bladder, liver, and head and neck cancers [2]. - Companies like Kangfang Biotech and Promis Biotech are exploring additional indications in China, suggesting a broadening of the PD(L)1*VEGF market [2]. - Other multinational corporations (MNCs) such as MSD, BMS, PFE, and ABBV are also likely to enter the PD(L)1*VEGF space, indicating a competitive landscape similar to the early days of PD(L)1 monoclonal antibodies [3].

Group 1 - The National Healthcare Security Administration has issued guidelines for the adjustment of the basic medical insurance catalog and the commercial health insurance innovative drug catalog for 2025, marking the first inclusion of commercial health insurance innovative drug catalog in the adjustment plan [1] - The Hang Seng Innovative Drug ETF (159316) has shown impressive performance, with a year-to-date increase of 67%, following the completion of a "purity revolution" that removed five CXO companies, focusing entirely on leading innovative drug firms [1][2] - The new index ensures "purity" through a three-tier screening process: excluding CXO companies, scoring based on R&D investment, and semi-annual rebalancing [1] Group 2 - The policy environment is favorable, with accelerated pilot programs for Class B medical insurance catalogs and CAR-T drugs included in "Huibao" for three consecutive years, with a maximum reimbursement of 500,000 yuan; nearly 40 innovative drugs are expected to be approved in the first half of 2025, potentially exceeding 50 for the entire year [2] - In the first five months of 2025, the total amount of license-out transactions by Chinese innovative drug companies reached 45.5 billion USD, surpassing the total for the first half of 2024, indicating a global revaluation of innovative drug value [2] Group 3 - The Hang Seng Innovative Drug ETF (159316) has significant holdings in companies like BeiGene and CanSino Biologics, with recent net inflows exceeding 17 million yuan and a 120% year-on-year increase in overseas sales for its holdings [3] - The EasyGo Innovative Drug ETF (516080) covers leading firms like HengRui Medicine, with a scale exceeding 400 million yuan, while the Medical ETF (512010) has a scale of over 20 billion yuan, with 35% allocated to innovative drugs, suitable for conservative investors [3] Group 4 - The innovative drug development success rate is below 10%, and some individual stocks may experience increased volatility due to speculative trading [4] - A "core + satellite" strategy is recommended, focusing 60%-70% on the Hang Seng Innovative Drug ETF and EasyGo Innovative Drug ETF, complemented by a diversified approach through the Hong Kong Stock Connect Medical ETF [4] - The combination of policy support and industry upgrades presents a historic opportunity for innovative drugs in 2025, with EasyGo providing efficient access for investors to participate in this transformation [4]

Group 1 - In the first half of 2025, 822 out of 993 comparable ordinary stock funds achieved positive performance, representing 83% of the total [1] - The top three performing funds saw gains exceeding 60%, with 华安医药生物股票发起式A at 66.44%, 华安医药生物股票发起式C at 66.07%, and 嘉实互融精选股票A at 60.26% [1][2] - 华安医药生物股票发起式 has a cumulative return of over 68% since its inception, heavily investing in pharmaceutical companies such as 三生制药 and 信达生物 [1] Group 2 - 嘉实互融精选股票 also focuses on pharmaceutical stocks, with top holdings including 康方生物 and 百济神州, and has shown significant growth exceeding 55% in the first half of 2025 [2] - Several other pharmaceutical-themed funds, including 平安医药精选股票 and 富国医药创新股票, also reported gains over 55% [2] - Conversely, 11 ordinary stock funds experienced declines exceeding 10%, with 长信消费精选量化股票C and A dropping 12.38% and 12.20% respectively, primarily due to their focus on the consumer sector [2][3] Group 3 - The 长信消费精选量化股票 fund, which is heavily invested in the liquor sector, has seen a cumulative decline of 50% since its establishment [3] - 北信瑞丰优选成长 fund, managed by a relatively inexperienced manager, has not included any pharmaceutical stocks in its top holdings since 2022, focusing instead on liquor stocks [3] - Other funds with significant declines include 民生加银优选股票, which fell by 10.64%, and 广发高端制造股票C and A, which dropped by 10.57% and 10.39% respectively [4]

Economic Indicators - The U.S. non-farm payrolls increased by 147,000 in June, better than expected, with the unemployment rate unexpectedly dropping to 4.1% [11] - The market has reduced expectations for a Federal Reserve rate cut in July and September following strong employment data [3][11] Trade and Tariffs - U.S. Treasury Secretary warned that about 100 countries may face at least a 10% reciprocal tariff, with Trump set to inform trade partners about unilateral tariff rates [11] - The "Big and Beautiful" bill passed the House despite two Republican defections, with Trump expected to sign it [14] Oil Production - OPEC+ is discussing an increase in production by 411,000 barrels per day in August [14] Stock Market Performance - U.S. stock indices rose, with the Dow Jones up 0.77%, S&P 500 up 0.83%, and Nasdaq up over 1.02% [5] - European stock indices also saw gains, with Germany's DAX30 up 0.61% and the UK's FTSE 100 up 0.55% [6] Commodity Prices - Spot gold fell significantly, dropping over $50 to a low of $3,311.65 before closing at $3,325.50 per ounce, down 0.94% [4][8] - WTI crude oil fluctuated around $66, closing down 0.58% at $66.23 per barrel, while Brent crude fell 0.39% to $68.51 [5][8] Chinese Market Developments - The A-share market saw all three major indices close in the green, with the Shanghai Composite Index up 0.18% and the Shenzhen Component Index up 1.17% [7] - The biotechnology sector showed strength, with several stocks rising over 10% [7]

Core Insights - Huaan Pharmaceutical Bio Stock Fund achieved the highest return among stock funds in the first half of 2025, with Huaan Pharmaceutical Bio Stock A (022690.OF) yielding 66.42% and Huaan Pharmaceutical Bio Stock C (022691.OF) yielding 66.07% [2][3] Fund Performance - The fund was established on December 25, 2024, with a total of 18.2574 million shares, including 14.2980 million A shares and 3.9594 million C shares [3] - The fund manager, Sang Xiangyu, subscribed to 10.00045 million A shares at inception [3] - In Q1 2025, A shares increased by 1.7 million shares and C shares increased by 3.25 million shares [4] - As of June 30, 2025, the fund's scale was only 35.77 million yuan, with nearly half being self-subscribed [5] Comparison with Other Funds - The fund's scale is significantly smaller compared to leading stock funds, making it easier to achieve high returns with a smaller asset base [6][8] - Sang Xiangyu also manages two other funds: Huaan Cultural and Health Flexible Allocation Mixed Fund, with a scale of 2.326 billion yuan and a return of -0.60%, ranking 1059 out of 2176 funds; and Huaan Huihong Selected Mixed Fund, with a scale of 162 million yuan and a return of 17.41%, ranking 89 out of 4667 funds [9][10] Risk of Fund Termination - According to the fund's prospectus, if the asset scale falls below 200 million yuan three years after the contract takes effect, the fund will automatically terminate and enter liquidation without a meeting of fund shareholders [11] - There is a potential risk of liquidation if the fund does not reach the 200 million yuan threshold, prompting the company to increase promotional efforts for the fund [11] Holdings Performance - The top five holdings of the fund performed well in the first half of 2025, with significant price increases: 283.54% for the largest holding, 72.54% for the second, 111.21% for the third, 49.36% for the fourth, and 193.79% for the fifth [7]

Group 1 - The core viewpoint of the news highlights a significant rise in the innovative drug sector, with the Hang Seng Biotechnology ETF (513280) increasing by 3.5% and showing net inflows for 3 out of the last 5 days, making it the only ETF in its index with positive growth in shares this year [1][3] - The A-share innovative drug sector also saw gains, with the Biopharmaceutical ETF (159839) rising by 1.72% [1] - Notable stock performances include Kangfang Biotech rising over 14%, and other companies like Innovent Biologics and CSPC Pharmaceutical Group also showing significant increases [3] Group 2 - Kangfang Biotech announced the completion of the first patient enrollment in the Phase Ia clinical study for its dual-target ADC drug AK146D1, which targets Trop2 and Nectin4 for treating advanced solid tumors [3][4] - AK146D1 is the first dual-target ADC drug to enter clinical stages for Kangfang Biotech, having received approvals from the FDA, TGA, and the National Medical Products Administration for clinical trials [4] - The drug aims to enhance efficacy and reduce resistance and toxicity by targeting both Trop2 and Nectin4, which are promising tumor targets [4] Group 3 - New policies have been introduced to support the development of innovative drugs, including measures from the National Healthcare Security Administration and the National Health Commission aimed at enhancing the quality of innovative drug development [4][5] - The introduction of a commercial health insurance directory for innovative drugs is expected to expand market opportunities and incentivize pharmaceutical companies to increase R&D efforts [5][6] - The measures include optimizing drug directory access policies and promoting the global market development of innovative drugs [5] Group 4 - The Hang Seng Biotechnology ETF (513280) is noted for its high proportion of innovative drugs and is the only ETF in its category to have net inflows this year, with a year-to-date share change of 11.40% [7] - The ETF is also recognized for having the lowest management fees among Hong Kong pharmaceutical ETFs, making it an attractive option for investors [7] - The Biopharmaceutical ETF (159839) focuses on leading companies in the sector, emphasizing a higher concentration and potential for growth [7]

Group 1 - The Hang Seng Index Company announced adjustments to the calculation methods of several indices, including the Hang Seng Hong Kong Stock Connect Innovative Drug Index, Hang Seng Innovative Drug Index, Hang Seng Biotechnology Index, and Hang Seng Hong Kong-US Biotechnology Index [1] - The adjustments aim to enhance the focus on pure innovative drug companies by excluding companies primarily engaged in the CXO industry, which includes Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMO), and Contract Development and Manufacturing Organizations (CDMO) [2][4] - The changes will result in a more concentrated index composition, with the top five constituents of the Hang Seng Hong Kong Stock Connect Innovative Drug Index shifting to companies like Innovent Biologics, BeiGene, and others, while the previous weight of excluded companies was approximately 18.1% [3] Group 2 - The Hang Seng Biotechnology Index will see a reduction in the number of constituents from 50 to a fixed number of 30, along with new trading qualification requirements under the Stock Connect program [6] - The Hang Seng Hong Kong-US Biotechnology Index will also reduce its constituent count from 60 to a fixed number of 40, indicating a significant decrease in the number of stocks included [9] - The adjustments to the indices will take effect on June 30, 2025, with the changes in constituent stocks implemented on September 8, 2025 [9]

Group 1 - Southbound funds recorded a net sell of 30.47 billion HKD today [1] - Alibaba-W, Tencent Holdings, and Kangfang Biotech experienced net sells of 32.26 billion HKD, 8.85 billion HKD, and 7.4 billion HKD respectively [1] - Meituan-W saw a contrary trend with a net buy of 9.87 billion HKD [1]